✦ LIBER ✦

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma

✍ Scribed by Flora Rozhansky; Ming-Hui Chen; Michael C. Cox; William Dahut; William D. Figg; Anthony V. D'Amico

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 91 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21576

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hormone therapy for patients with prosta

Hormone therapy for patients with prostate carcinoma

✍ Laurence Klotz 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

Mitoxantrone in patients with prostate s

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma

✍ Robert S. DiPaola; Eric S. Chenven; Weichung J. Shih; Yong Lin; Peter Amenta; Su 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 2 views

A Phase II study of oral idarubicin as a

A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time

✍ Hans-Peter Schmid; Rudolf Maibach; Juerg Bernhard; Franz Hering; Silvia Hanselma 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## Background: Treatment of hormone-refractory prostate carcinoma with chemotherapy is purely palliative, and reported response rates have been low. at the time this study was conducted, there was an urgent need for a trial using potentially efficacious drugs, with quality of life (ql), and serial

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

Higher prostate-specific antigen levels

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase

✍ Wanling Xie; Mari Nakabayashi; Meredith M. Regan; William K. Oh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Higher prostate‐specific antigen (PSA) and alkaline phosphatase (ALK‐P) levels predicted worse survival in men with metastatic hormone‐refractory prostate cancer (HRPC). In the current study, the authors evaluated the combined effects of PSA and ALK‐P on survival. ## ME

Radiotherapy for localized prostate carc

Radiotherapy for localized prostate carcinoma : The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

✍ Juanita M. Crook; Yasir A. Bahadur; R. Gregory Bociek; Gad A. Perry; Susan J. Ro 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru